Diabetes device trials are research studies where manufacturers and medical teams test new tools and technologies designed to help people manage blood sugar levels. These trials happen because the FDA requires proof that devices work safely before they can be sold to the public. In 2026, several new devices are expected to move through different stages of testing, which means this year represents an important checkpoint for innovation in diabetes care.
Learn About Paying Your FGUA Bill Online →
Unlike medication trials that focus on how a drug affects the body, device trials test whether a physical product does what it's supposed to do. This might be a new continuous glucose monitor (CGM) with better accuracy, an insulin pump with smarter delivery features, or an app that connects multiple devices to give a clearer picture of blood sugar patterns. The testing happens in phases, and each phase answers different questions about whether the device is safe and whether it actually works.
Why does 2026 specifically matter? Several devices that began trials in 2023 and 2024 are reaching their later testing phases now. This means decisions about whether to move forward with FDA approval could happen throughout 2026. Additionally, companies are launching new trials for devices that didn't exist five years ago—technology that combines artificial intelligence with insulin delivery, or monitors that don't require finger sticks at all.
Understanding how these trials work helps you see what might become available in the coming years. It also explains why a device you heard about last year might not be in stores yet, and why some devices that seem similar have different features or accuracy levels.
Practical takeaway: Device trials are how new diabetes tools get tested before reaching patients. Knowing that trials happen in stages helps you understand why innovation takes time and why the FDA requires proof before approving new devices.
Diabetes device trials follow a structured path with distinct phases, and understanding each one helps you follow what's happening in 2026. Not every trial goes through all phases in the same way, and some devices skip certain steps depending on how similar they are to devices already on the market.
Free Guide to Pay by Plate Illinois Billing →
Phase I trials are the earliest stage and involve small groups of people—typically 20 to 100 volunteers. These trials focus on basic safety questions: Does the device cause any harmful reactions? Does it work at all, even in a basic way? For a continuous glucose monitor, Phase I might test whether the sensor stays attached properly, reads blood sugar readings without causing skin irritation, and gives numbers that are roughly in the right ballpark. Phase I trials don't try to prove the device is better than existing options—they just try to show it won't hurt people and does something close to what it's supposed to do.
Phase II trials expand the group to several hundred people and last longer—often six months to a year. Now the focus shifts to asking: How accurate is this device compared to the standard way of measuring? For an insulin pump, Phase II tests whether the automatic delivery system keeps blood sugar in target range better than manual insulin shots. For a glucose meter, it tests whether the readings match lab results closely enough to be trusted for making medical decisions. This is where manufacturers start collecting the data they'll need for FDA approval.
Phase III trials involve hundreds to thousands of people and can last one to three years. These are the large-scale studies that answer whether the device works in real-world conditions with different types of people. A Phase III trial for a new CGM might include teenagers, adults, pregnant women, and people with other health conditions to make sure the device works for everyone, not just the healthy volunteers in Phase I. This is also where rare side effects sometimes show up—issues that only appear in a few people out of thousands.
Phase IV trials happen after FDA approval and involve monitoring what happens when the device is used by millions of people in regular life. These trials sometimes find issues that didn't appear during earlier testing. In 2026, several devices approved in recent years are still in Phase IV monitoring, which is why you might hear news about adjustments or improvements to devices that already exist.
Practical takeaway: Device trials move through four phases that gradually involve more people and longer testing periods. Knowing which phase a device is in tells you how much testing has already happened and how much longer before it might reach patients.
Continuous glucose monitors—devices that track blood sugar throughout the day—represent one of the biggest areas of device innovation for 2026. Multiple companies have sensors in late-stage testing, and several announcements about new products are expected this year. Understanding what's being tested helps you know what features might become standard in coming years.
Free Guide to Mold Removal Methods for Walls →
One major focus is accuracy over longer wearing periods. Current CGMs typically need replacement every 7 to 14 days, and accuracy sometimes drifts toward the end of that period. Several trials ongoing in 2026 are testing sensors that can stay on the skin for 14 to 30 days while maintaining consistent accuracy. This matters because it reduces how often people need to change sensors and reduces the chance of losing data during the switch. One device in Phase III trials uses a different sensor design that measures glucose in the fluid between cells rather than blood directly, which some companies believe could improve long-term accuracy.
Another area of testing involves reducing the size and visibility of sensors. Current CGMs are about the size of a large coin and somewhat noticeable on the skin. Several devices in 2026 trials use smaller sensors that lie completely flush with the skin or are barely raised, which appeals to people who want less visible diabetes management. One such device in Phase II trials is expected to reach Phase III in 2026.
Non-invasive glucose monitoring—measuring blood sugar without inserting anything under the skin—remains a goal that several companies are pursuing. These devices might use light, sound waves, or electrical signals to measure glucose through the skin. While no fully non-invasive monitor has been approved yet, trials continuing in 2026 are testing prototypes in real-world conditions. These are still early-stage and likely years away from market availability, but they represent the future direction of the field.
Integration with smartphones is becoming standard in new CGM designs entering trials. Several devices in Phase II and Phase III testing connect directly to phones via Bluetooth, eliminating the need for a separate receiver. Some go further by offering cloud storage of readings, allowing family members or doctors to see data in real time. Trials are testing how this affects user behavior—for example, whether people check their readings more often or make better decisions when they have more immediate access to data.
Practical takeaway: CGM trials in 2026 focus on longer wear time, smaller designs, improved accuracy, and better connectivity. These advances suggest that future glucose monitors will be less intrusive and more integrated with daily life than current options.
Insulin pumps and closed-loop systems—devices that automatically adjust insulin delivery based on blood sugar readings—are seeing rapid innovation in 2026. These trials represent a shift toward artificial intelligence making more decisions about how much insulin to give and when to give it.
How to Delete Your Fitbit Account Guide →
Closed-loop systems, sometimes called "artificial pancreas" technology, combine a CGM with an insulin pump and use algorithms to automatically increase or decrease insulin delivery. Several systems already exist on the market, but trials in 2026 are testing newer versions with smarter algorithms. One system in Phase III trials adjusts insulin delivery not just based on current blood sugar, but based on predictions about where blood sugar is heading in the next 30 minutes. Another system being tested can switch between different insulin types depending on whether blood sugar is dropping slowly or quickly, which could prevent both high and low blood sugar events more effectively than current systems.
Faster-acting insulin formulations are being tested alongside these devices. One trial involves a new insulin designed to work in 15 minutes rather than the typical 20 to 30 minutes. When paired with a closed-loop system, faster insulin could mean the system responds more quickly to high blood sugar, keeping it in range better. This trial is expected to reach Phase III in 2026 after successful Phase II results.
Smaller and lighter pump designs are under development by multiple manufacturers. Current insulin pumps are roughly the size of a pager, and while that's small, some people want something even more discreet. Several trials in 2026 involve patch pumps—devices that stick directly to the skin like a sensor, with no tubing or separate device to carry. One patch pump design eliminates the need to insert a needle; instead, a tiny hollow tube stays under the skin. Another approach
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.